Angel Physicians Fund

Alphyn Biologics is a life science company focused on developing innovative drug therapies for skin diseases, particularly severe and common skin infections. The company's primary target is infections caused by drug-resistant bacteria, specifically methicillin-resistant Staphylococcus aureus (MRSA). Utilizing its proprietary Multi-Target Therapeutic (MTT) platform, Alphyn Biologics creates topical treatments derived from a tropical plant known for its natural antibacterial properties. This approach aims to address shortcomings in existing treatments, such as efficacy, side effects, and patient tolerability, ultimately providing a safe and effective solution for patients suffering from bacterial skin infections.

PanTher Therapeutics, Inc. is a biotechnology company focused on developing innovative drug-delivery treatments for cancer. Founded in 2014 and based in Cambridge, Massachusetts, the company has created a proprietary platform that enhances therapeutic responses while minimizing side effects. This technology allows for direct and sustained delivery of drugs to tumor sites, thereby improving the efficacy of treatment and reducing the toxicity often associated with traditional intravenous or oral administration methods. PanTher's distinctive targeting capability positions it to address some of the most challenging cancer types, with a lead investigational candidate aimed at treating pancreatic cancer.

Elucid is a Boston-based biotechnology and medical technology company dedicated to enhancing cardiovascular diagnostic imaging through machine learning. The company has developed ElucidVivo, the first FDA-cleared software that evaluates plaque vulnerability from a single computed tomography angiography scan, aiding in the assessment of heart attack and stroke risks as well as informing treatment decisions. Elucid's technology enables objective quantification of arterial plaque extent and stability, providing a cost-effective and non-invasive means of capturing essential patient health information. In addition to its proprietary software, Elucid collaborates with pharmaceutical companies, healthcare providers, and research organizations to offer quantitative image analysis services, ultimately aiming to improve patient outcomes in cardiovascular care.

S4 Medical Corp is a medical device company specializing in innovations for catheter ablation treatment of atrial fibrillation. Founded in 2017 and based in Cleveland, Ohio, S4 Medical has developed an eSolution device that aims to reduce complications to the esophagus during ablation procedures. This device provides an effective means for electrophysiologists to protect the esophagus and strategically determine when and where to deviate it, thereby minimizing the risk of thermal injury associated with these cardiac interventions. The company's focus on enhancing safety during atrial fibrillation treatments underscores its commitment to improving patient outcomes in the field of cardiology.

Moray Medical is a company focused on developing innovative robotic delivery systems for structural heart therapies, specifically targeting edge-to-edge valve leaflet repair. The company aims to enhance the quality of life for millions affected by leaky heart valves by providing cardiologists with advanced tools for mitral valve clip therapies. Moray Medical's proprietary microfluidic robotics technology enables the precise and safe delivery of treatments, utilizing a compact, reusable fluid-drive system that features a digital interface for maneuvering flexible delivery catheters with ease, akin to using a computer cursor. This approach allows for cost-effective interventions, making life-saving heart valve therapies more accessible to a broader range of patients in need.

Foldax, Inc., established in 2013 and headquartered in Salt Lake City, Utah, specializes in the design and manufacture of synthetic heart valves. The company's primary product is the Tria biopolymer heart valve, which can be implanted percutaneously or surgically to treat aortic, mitral, or tricuspid valve disease. Foldax aims to provide non-thrombogenic valves at a significantly lower cost compared to existing artificial or tissue valves, reducing the need for lifelong anticoagulant drugs and their associated risks. The company operates in the manufacturing sector, focusing on life polymer technology to create durable and effective heart valve replacements.